UTMD Stock Recent News

I reiterate my strong buy on UTMD, citing its robust balance sheet, disciplined capital allocation, and 43% upside to my $82.22 price target. Revenue headwinds appear to be stabilizing, with legendary value investor Charles Brandes taking a 7.4% stake, signaling renewed institutional interest. Key risks include Filshie Clip litigation, declining China sales, and succession planning, but UTMD's undervaluation and cash reserves limit downside.

SALT LAKE CITY, UT / ACCESS Newswire / May 6, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on July 3, 2025 to stockholders of record at the close of business on June 16, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.

In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside.

UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.

SALT LAKE CITY, UT / ACCESS Newswire / April 29, 2025 / In the first calendar quarter (1Q) of 2025, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results consistent with its previously announced projections for calendar year 2025. Summary of results.

Utah Medical Products develops and manufactures medical devices focused on women's health, obstetrics, gynecology, and blood pressure monitoring. The company's stock price has declined due to a drop in sales from a key U.S. customer, weaker performance in international markets, and ongoing litigation. Despite recent challenges, the company has a consistent track record of profitability, a fortress balance sheet, and a disciplined capital allocator in the CEO.

SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per share of common stock payable on April 3, 2025 to stockholders of record at the close of business on March 14, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.

UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.

SALT LAKE CITY, UT / ACCESS Newswire / January 28, 2025 / With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (NASDAQ:UTMD) concluded a year of contraction. UTMD's stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market.

SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.